According to our new research study on “Image Guided Radiotherapy Market Forecast to 2030 – Global Analysis – by Type, Application, Imaging Type, and End User,” the market was valued at US$ 1,814.25 million in 2022 and is projected to reach US$ 5,650.72 million by 2030; it is estimated to register a CAGR of 15.3% during 2022–2030. The market’s growth is due to the rising prevalence of cancer worldwide and the introduction of technologically advanced systems. Further, cancer screening programs and the implementation of standard guidelines are expected to provide growth opportunities for the market growth. However, the high cost of image-guided radiotherapy treatment will hinder market growth.
Coverage: Type (Product and Services), Application (Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Prostrate Cancer, Gynecological Cancers, Head and Neck Cancer, and Others), Imaging Type (Magnetic Resonance Imaging (MRI), Positron Emission Tomography, Computed Tomography Imaging, and Others), End Users (Hospitals, Oncology Centers, and Radiotherapy Centers), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Download Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00009118/
Leading players are implementing strategies such as expanding and diversifying their market presence, launching new products, and acquiring a new customer base to tap prevailing business opportunities.
- In May 2023, Philips expanded its mobile C-arm portfolio with Zenition 10.
- In April 2023, GE HealthCare expanded its portfolio of magnetic resonance imaging (MRI) contrast agents with the launch of Pixxoscan. It provides customers access to two leading macrocyclic molecules: Clariscan (gadoteric acid) and Pixxoscan (gadobutrol).
- In June 2023, GE HealthCare announced its plans to expand its PET/MR capabilities with AIR technologies to improve diagnostic precision and simplify treatment evaluation while increasing patient comfort.
- In September 2022, the National Medical Products Administration (NMPA), China’s regulatory authority, approved the sale and use of ViewRay’s MRIdian MRI-guided radiation therapy system.
- In March 2022, Hwasun Hospital of Chonnam National University introduced the “Halcyon 3.0” radiotherapy system and used it for comprehensive treatment. Halcyon 3.0 is a state-of-the-art radiation cancer treatment device that can deliver intensity-modulated radiation therapy based on real-time image guidance.
The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are the primary and secondary sources referred to while preparing the image-guided radiotherapy market report.
About Us:
The Insight Partners is a market research solution and consultation company. Specializing in syndicate market research, our team helps clients in their hunt for revenue pockets in several industries. A team of 250+ research experts is dedicated to offering the most relevant, data-driven, and trustworthy market insights and consultation.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us
The Insight Partners
Phone: +1-646-491-9876
E-mail: [email protected]
